Clinical Trials

The purpose of this study is to generate endothelial and smooth muscle cell lines from patients with brain arteriovenous malformations (AVM)s for subsequent use in cell culture (and eventually animal models) in order to delineate the underlying cell, molecular, genetic, and epigenetic features of brain AVMs.

The purpose of this study is to offer the best management possible for patients with brain arteriovenous malformations (AVMs) (ruptured or unruptured) in terms of long-term outcomes, despite the presence of uncertainty.

The purpose of this study is to identify robust, clinically-applicable risk factors for stroke and death in unruptured bAVMs, and study long-term outcomes in patients with and without treatment.

This study aims to develop a novel ultra-low dose chest CT technology for use in HHT patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.

The primary objective of this study is to gather post market data on the Penumbra SMART Coil™ System in the treatment of intracranial aneurysms and other malformations.

The purpose of this study is to comparatively evaluate the use of the GLOW800 visualization tool for ICG-VA versus the standard of care visualization tool FL800.

This study is one of the three projects of an NIH Rare Disease Clinical Research Consortium. A "consortium" is a group of centres sharing information and resources to perform research. The consortium research focuses on brain blood vessel malformations in three different rare diseases.

The focus of this specific study is on Hemorrhagic Telangiectasia (HHT).

HHT is a condition characterized by blood vessel malformations, called telangiectasia and arteriovenous malformations (AVMs), occurring in the brain, nose, lungs, stomach, bowels and liver. Brain AVMs (BAVMs) in HHT are difficult to study because they are rare, affecting approximately 10% of people ...

The purpose of this study is to learn more about arteriovenous malformation (AVM), a type of blood vessel abnormality in the brain. 

The purpose of this study is to assess if using holography/ Augmented Reality and 3D-printed models to visualize intracranial diseases and aid in patient education.

The purpose is to study the effects of intraventricular nicardipine, a vasodilatory agent, on VP and secondary outcomes of stroke and functional outcome at 30 and 90 days compared to those not treated with this agent.

The aim of this study is to create a state-wide biorepository and resource center for cerebrovascular diseases in Florida. The Center will collect and store detailed phenotypic information, DNA, and other biofluids on affected subjects with diverse cerebrovascular conditions, including, but not limited to, ischemic stroke, transient ischemic attack (TIA), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), vascular dementia (VAD), anoxic brain injury, unruptured intracranial aneurysm (UIA), cavernous malformation, arteriovenous malformations (AVM), carotid and vertebral arterial dissections, symptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis, non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH), cerebral venous thrombosis (CVT), moyamoya disease, fibrosmuscular dysplasia (FMD), non-traumatic, angiography-negative subarachnoid ...